AP
WVE icon

Atlas Principals’s Wave Life Sciences WVE Stock Holding History

Atlas Principals’s Portfolio WVE Stock Details WVE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-30,000
Closed -$312K – 43
2020
Q2 		$312K Buy
30,000
+10,000
+50% +$94.1K 0.23% 36
2020
Q1 		$187K Hold
20,000
– – 0.18% 38
2019
Q4 		$160K Buy
+20,000
New +$490K 0.06% 41

Other funds holding WVE

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Atlas Principals's WVE Position: Q3 2020 in Review

Atlas Principals sold out of Wave Life Sciences (WVE) in Q3 2020, closing a stake of 30,000 shares — an estimated $312K sold.

Atlas Principals first reported a position in WVE in Q4 2019 and held it in 3 quarters. The position peaked at $312K in Q2 2020. 110 funds tracked by Wall St. Rank hold WVE as of Q3 2020.

  • Atlas Principals reported no remaining Wave Life Sciences position as of Q3 2020 after selling out during the quarter.
  • Atlas Principals sold 30,000 Wave Life Sciences shares in Q3 2020, an estimated $312K.
  • Atlas Principals first reported a position in Wave Life Sciences in Q4 2019 and held it in 3 quarters.
  • Atlas Principals's Wave Life Sciences position peaked at $312K in Q2 2020.
  • 110 funds tracked by Wall St. Rank held Wave Life Sciences as of Q3 2020.

Based on Atlas Principals's 13F filing for Q3 2020, filed 16 Nov 2020.